FDA警告:供体干细胞移植后长期使用Zithromax(阿奇霉素)会增加癌症复发风险

2018-08-05 MedSci MedSci原创

对于接受供体干细胞移植的血液或淋巴结癌症患者,不应长期给予抗生素Zithromax(阿奇霉素)以预防某种炎症性肺病。临床试验的结果发现,在这些长期使用Zithromax(阿奇霉素)患者中,血液和淋巴结(包括死亡)的癌症的复发率增加。FDA正在审核其他数据,并会在审核完成后传达结论和建议。

对于接受供体干细胞移植的血液或淋巴结癌症患者,不应长期给予抗生素Zithromax(阿奇霉素)以预防某种炎症性肺病。临床试验的结果发现,在这些长期使用Zithromax(阿奇霉素)患中,血液和淋巴结(包括死亡)的癌症的复发率增加。FDA正在审核其他数据,并会在审核完成后传达结论和建议。

严重肺病,又称为闭塞性细支气管炎综合征,是由肺部气道炎症和瘢痕引起的,导致严重的呼吸急促和干咳。接受干细胞移植的癌症患者存在闭塞性细支气管炎综合征的风险。Zithromax(阿奇霉素)是FDA批准的抗生素,用于治疗影响肺、鼻窦、皮肤和身体其他部位的多种感染。该药物已使用超过26年,它以ZithromaxZmax品牌销售,并存在多种仿制药。然而阿奇霉素未被批准用于预防闭塞性细支气管炎综合征,因此供体干细胞移植后长期使用Zithromax(阿奇霉素)以预防严重肺病的结论仍需严格的审查。


原始出处:

http://www.firstwordpharma.com/node/1583039?tsid=4#axzz5NCMJrdAy

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1905508, encodeId=3072190550821, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Tue Jun 25 02:08:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631861, encodeId=b558163186128, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Fri May 24 07:08:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010158, encodeId=c2ab20101588e, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Tue May 14 06:08:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658876, encodeId=59f316588e67f, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Sun Aug 05 15:08:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425300, encodeId=52c51425300f6, content=<a href='/topic/show?id=7eb6e134273' target=_blank style='color:#2F92EE;'>#癌症复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71342, encryptionId=7eb6e134273, topicName=癌症复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fad3959854, createdName=lq0302, createdTime=Tue Aug 07 06:08:00 CST 2018, time=2018-08-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1905508, encodeId=3072190550821, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Tue Jun 25 02:08:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631861, encodeId=b558163186128, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Fri May 24 07:08:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010158, encodeId=c2ab20101588e, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Tue May 14 06:08:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658876, encodeId=59f316588e67f, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Sun Aug 05 15:08:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425300, encodeId=52c51425300f6, content=<a href='/topic/show?id=7eb6e134273' target=_blank style='color:#2F92EE;'>#癌症复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71342, encryptionId=7eb6e134273, topicName=癌症复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fad3959854, createdName=lq0302, createdTime=Tue Aug 07 06:08:00 CST 2018, time=2018-08-07, status=1, ipAttribution=)]
    2019-05-24 feather85
  3. [GetPortalCommentsPageByObjectIdResponse(id=1905508, encodeId=3072190550821, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Tue Jun 25 02:08:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631861, encodeId=b558163186128, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Fri May 24 07:08:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010158, encodeId=c2ab20101588e, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Tue May 14 06:08:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658876, encodeId=59f316588e67f, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Sun Aug 05 15:08:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425300, encodeId=52c51425300f6, content=<a href='/topic/show?id=7eb6e134273' target=_blank style='color:#2F92EE;'>#癌症复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71342, encryptionId=7eb6e134273, topicName=癌症复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fad3959854, createdName=lq0302, createdTime=Tue Aug 07 06:08:00 CST 2018, time=2018-08-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1905508, encodeId=3072190550821, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Tue Jun 25 02:08:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631861, encodeId=b558163186128, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Fri May 24 07:08:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010158, encodeId=c2ab20101588e, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Tue May 14 06:08:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658876, encodeId=59f316588e67f, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Sun Aug 05 15:08:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425300, encodeId=52c51425300f6, content=<a href='/topic/show?id=7eb6e134273' target=_blank style='color:#2F92EE;'>#癌症复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71342, encryptionId=7eb6e134273, topicName=癌症复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fad3959854, createdName=lq0302, createdTime=Tue Aug 07 06:08:00 CST 2018, time=2018-08-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1905508, encodeId=3072190550821, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Tue Jun 25 02:08:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631861, encodeId=b558163186128, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Fri May 24 07:08:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010158, encodeId=c2ab20101588e, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Tue May 14 06:08:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658876, encodeId=59f316588e67f, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Sun Aug 05 15:08:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425300, encodeId=52c51425300f6, content=<a href='/topic/show?id=7eb6e134273' target=_blank style='color:#2F92EE;'>#癌症复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71342, encryptionId=7eb6e134273, topicName=癌症复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fad3959854, createdName=lq0302, createdTime=Tue Aug 07 06:08:00 CST 2018, time=2018-08-07, status=1, ipAttribution=)]

相关资讯

CLIN CANCER RES:伊匹单抗联合来那度胺治疗干细胞移植后淋巴系统恶性肿瘤

造血干细胞移植后阻止或治疗淋巴系统恶性肿瘤复发需要完整的策略。CLIN CANCER RES近期发表了一篇文章,研究来那度胺是否可以增强CTLA-4抑制剂伊匹单抗的抗肿瘤效果

Stem Cells Int:用外泌体修补“破碎”的心脏

干细胞移植治疗是一种很有前景的修复损伤心脏组织并使其再生的辅助手段;然而,由于缺血心脏中移植细胞的存活不佳,一般仅能观察到心脏功能的适度改善。因此,对于可以帮助减轻心脏损伤的新疗法亟待出现。最近的研究已经证明干细胞释放的外泌体可以作为心脏修复的潜在的无细胞治疗剂。曾经一度被认为仅仅是一种细胞废物的外泌体或细胞外纳米粒子已被证明在包括短距离和长距离的细胞间通讯在内的生理功能中起着至关重要的作用。

JCO:血液系统恶性肿瘤干细胞移植后认知功能

清髓性异体干细胞移植(HCT)后认知功能损害已得到公认,但是低强度异体或自体HCT后对认知功能的影响尚不清楚。JCO近期发表了一篇文章研究这一问题。

干细胞移植会成为肥胖症的治疗良药吗?

贝鲁特阿拉伯大学(Beirut Arab University,BAU)健康科学学院的一组科研人员通过研究脂肪衍生MSCs(AD-MSCs)对肥胖和相关并发症的影响和建立可行性动物模型,以证明其对人类临床治疗的效果。

Blood:干细胞移植后补充维生素A可能能抑制移植物抗宿主病的发生

这些数据支持了研究人员的假设,即低水平的维生素A积极促进胃肠道发生移植物抗宿主病的概率。未来补充维生素A可能会改善移植结果。

JCO:干细胞移植治疗轻链淀粉样变:早期死亡率降低

自体干细胞移植(ASCT)用来治疗免疫球蛋白轻链(AL)淀粉样变患者的时间已超过20年。但是早期的实践经验发现治疗早期死亡率较高。JCO近期发表了一篇文章,研究20年间自体干细胞移植治疗轻链淀粉样变早期死亡率的变化。